Stryker Corp. (NYSE:SYK) VP Yin C. Becker sold 1,111 shares of the firm’s stock in a transaction that occurred on Thursday, October 6th. The stock was sold at an average price of $117.00, for a total value of $129,987.00. Following the completion of the sale, the vice president now owns 16,939 shares of the company’s stock, valued at approximately $1,981,863. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Stryker Corp. (NYSE:SYK) opened at 113.58 on Friday. The firm has a market cap of $42.51 billion, a P/E ratio of 26.78 and a beta of 0.72. The firm has a 50 day moving average price of $115.21 and a 200 day moving average price of $114.05. Stryker Corp. has a 1-year low of $86.68 and a 1-year high of $123.55.
Stryker Corp. (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 21st. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.02. The company earned $2.84 billion during the quarter, compared to the consensus estimate of $2.79 billion. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. Analysts anticipate that Stryker Corp. will post $5.76 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.52 annualized dividend and a dividend yield of 1.34%. Stryker Corp.’s dividend payout ratio (DPR) is presently 35.85%.
A number of equities analysts have recently issued reports on the company. Jefferies Group reissued a “hold” rating and issued a $120.00 target price (up from $113.00) on shares of Stryker Corp. in a report on Monday, July 25th. Credit Suisse Group AG reissued an “outperform” rating and issued a $124.00 target price (up from $110.00) on shares of Stryker Corp. in a report on Tuesday, July 19th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $119.00 target price on shares of Stryker Corp. in a report on Friday, July 22nd. Brean Capital reissued a “buy” rating and issued a $125.00 target price (up from $121.00) on shares of Stryker Corp. in a report on Monday, July 25th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $130.00 target price on shares of Stryker Corp. in a report on Sunday, July 24th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $114.91.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. LSV Asset Management bought a new position in shares of Stryker Corp. during the second quarter valued at about $107,000. Global X Management Co. LLC increased its stake in Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock worth $119,000 after buying an additional 698 shares during the last quarter. Carroll Financial Associates Inc. increased its stake in Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock worth $130,000 after buying an additional 476 shares during the last quarter. CWM LLC bought a new stake in Stryker Corp. during the second quarter worth $150,000. Finally, Daiwa SB Investments Ltd. bought a new stake in Stryker Corp. during the third quarter worth $163,000. Institutional investors own 75.49% of the company’s stock.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.